• Print
  • Share
close

Share this on...

Share this site with others using one of these sharing tools.

 

Link to this article

To link to this article, paste this block of HTML code onto your webpage.

Guidelines for sites linking to mayoclinic.org

Mayo Clinic Proceedings: Researchers Find Evidence of Survival Gains in Bone Marrow Disease

Friday, December 11, 2009

ROCHESTER, Minn. — A recent study, published in the December issue of Mayo Clinic Proceedings, demonstrates new survival data for the blood disorder myelofibrosis. This retrospective study is the largest ever conducted in young patients with primary myelofibrosis.

    VIDEO ALERT: Additional audio and video resources, including excerpts from an interview with Dr. Tefferi describing the research, are available on the Mayo Clinic Proceedings Web site.

Myelofibrosis is a serious disorder that disrupts the body's normal production of blood cells. The result is extensive scarring in the bone marrow, leading to severe anemia, weakness, fatigue and often, an enlarged spleen and liver.

"In the past 20 years, management of primary myelofibrosis has incorporated new treatment approaches, but survival benefits for patients have not been confirmed," says Ayalew Tefferi, M.D., senior author of the study and a Mayo Clinic hematologist. "Our study reviewed almost 30 years of data on myelofibrosis to obtain mature survival data in the particular patient population."

Study findings suggest that high- to intermediate-risk patients in whom the diagnosis of primary myelofibrosis was made after 1986 lived longer than those whose diagnosis was made earlier. The improvement in survival was most impressive for patients whose diagnosis was made in the most recent decade (ie, 1996-2005) in which median survival was not reached.

"Such retrospective studies cannot accurately identify the reasons for improved survival but alert clinical investigators to avoid using historical controls to determine the value of new treatment modalities such as allogeneic hematopoietic cell transplantation," says Dr. Tefferi.

"These observations are encouraging and suggest a beneficial effect from modern therapeutic approaches in myelofibrosis. The current findings are based on retrospective observation and need to be validated in properly designed prospective studies."

A peer-reviewed journal, Mayo Clinic Proceedings publishes original articles and reviews dealing with clinical and laboratory medicine, clinical research, basic science research and clinical epidemiology. Mayo Clinic Proceedings is published monthly by Mayo Foundation for Medical Education and Research as part of its commitment to the medical education of physicians. The journal has been published for more than 80 years and has a circulation of 130,000 nationally and internationally. Articles are available online.

###

About Mayo Clinic

Mayo Clinic is a nonprofit worldwide leader in medical care, research and education for people from all walks of life. For more information, visit MayoClinic.com or MayoClinic.org/news.

Media Contact

Rebecca Eisenman
507-284-5005 (days)
507-284-2511 (evenings)
newsbureau@mayo.edu

Patient & Visitor Guide

Learn more about becoming a patient at Mayo Clinic in the Patient & Visitor Guide.

  • Print

Find Mayo Clinic on


Terms of Use and Information Applicable to this Site
Copyright ©2001-2012 Mayo Foundation for Medical Education and Research. All Rights Reserved.

.